Sunday 18 October 2026
Export LTGO’s income statement to Excel — free account
Latigo Biotherapeutics Inc
LTGO
Insiders bought in the last twelve months.
13.98
0.78
−5.28%
Follow LTGO
| Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|
Current Ratio |
— | 4.00 | 1.15 |
Net Debt/EBITDA |
0.00 | 0.00 | 2.14 |
Debt/Assets |
— | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | — | 0.00 |
Interest Coverage |
— | — | (102.82) |
Research and Development Expense of Revenue |
0.00% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
0.00 | 0.00 | 59.03 |
Shareholders Equity per Share |
0.00 | 0.00 | 13.37 |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
0.00 | 0.00 | 13.37 |
| Other line items | |||
Quick Ratio |
— | 3.77 | 1.07 |
Revenue per Share |
0.00 | — | 0.00 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Working Capital |
— | 55.38 | 7.62 |
Net Current Asset Value |
— | 55.22 | 6.94 |
Columns are period end dates · fundamentals updated 29 Sep 2026